AstraZeneca completes Ardea takeover
AstraZeneca said it had successfully completed its acquisition of California-based biotechnology company Ardea Biosciences.
AstraZeneca said it had successfully completed its acquisition of California-based biotechnology company Ardea Biosciences.
The pharmaceutical giant said the $1.2bn deal would strengthen its late-stage pipeline with the addition of lesinurad, which is aimed at patients with gout.
MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
At the time the deal completed the prices had equalised with Ardea shares changing hands at $31.96 at the close on Tuesday.
With the takeover complete, each outstanding share of Ardea common stock has been cancelled and converted into the right to receive $32.00, in cash, without interest.
Shares of Ardea have ceased trading on the NASDAQ.
-
Best places to live in England and Wales in 2026 – and how much they costCriteria like value for money, natural beauty, good schools, jobs and a high quality of life are key for those looking at areas to buy a house – but how much will it cost you to live in a high ranking town or city? We reveal the best places to live in England and Wales.
-
London house prices: Is the capital's property boom over?Buyers and investors have always been drawn towards the capital’s property market. But as house prices stall, is the market as lucrative as it once was and are buyers and investors still interested?
